Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹13 Cr
Revenue (TTM)
₹1 Cr
Net Profit (TTM)
₹0 Cr
ROE
8.7 %
ROCE
3.8 %
P/E Ratio
503.5
P/B Ratio
22.6
Industry P/E
503.52
EV/EBITDA
224.3
Div. Yield
0 %
Debt to Equity
0
Book Value
₹1
EPS
₹0
Face value
10
Shares outstanding
5,468,300
CFO
₹0.23 Cr
EBITDA
₹-0.31 Cr
Net Profit
₹-3.27 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rubra Medicaments
| 76.4 | 3.4 | 35.4 | 143.1 | -- | 75.3 | 23.6 |
|
BSE Healthcare*
| -4.2 | 2.0 | 6.9 | 16.5 | 27.2 | 21.8 | 10.4 |
|
BSE Small Cap#
| -3.2 | 3.9 | 17.8 | 2.6 | 30.0 | 34.4 | 17.1 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2018
|
|---|---|---|---|---|---|
|
Rubra Medicaments
| 168.0 | 3.1 | 11.1 | 70.3 | -67.4 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rubra Medicaments
|
23.0 | 12.6 | 0.5 | 0.0 | 9.2 | 4.1 | 503.5 | 22.6 |
| 1,107.6 | 9,061.3 | 1,006.9 | 160.4 | 20.4 | 12.6 | 57.1 | 6.9 | |
| 1,143.3 | 4,960.2 | 5,095.8 | 107.4 | 2.8 | 5.6 | 52.3 | 2.9 | |
| 28.6 | 12.6 | 28.7 | 0.2 | 7.3 | -245.2 | 74.5 | 2.7 | |
| 44.0 | 54.4 | 25.5 | -0.6 | -13.9 | -0.5 | -- | 0.4 | |
| 41.2 | 25.8 | 0.8 | 0.3 | -26.3 | 2.6 | 105.4 | 2.7 | |
| 5,960.0 | 9,886.6 | 1,218.1 | 251.2 | 28.1 | -- | 39.4 | 18.4 | |
| 917.9 | 8,994.8 | 1,286.4 | 79.6 | 15.9 | 4.7 | 114.9 | 3.8 | |
| 2.2 | 8.6 | 7.4 | -0.7 | -5.1 | -15.2 | -- | 2.2 | |
| 14.4 | 154.4 | 54.6 | 4.5 | 5.6 | 4.4 | 71.1 | 1.5 |
No Review & Analysis are available.
Rubra Medicaments Limited engages in the trade of pharmaceuticals, and other medical and surgical products in India. The company was incorporated in 1991 and is based in Mumbai, India.
Incorporated
1991
Chairman
--
Managing Director
--
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Rubra Medicaments Ltd stood at ₹ 1 Cr as on 31-Mar-25
The share price of Rubra Medicaments Ltd is ₹23.02 (BSE) as of 18-Jun-2025 IST. Rubra Medicaments Ltd has given a return of 143.08% in the last 1 years.
Rubra Medicaments Ltd has a market capitalisation of ₹ 13 Cr as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Rubra Medicaments Ltd is 22.61 times as on 18-Jun-2025, a 942% premium to its peers’ median range of 2.17 times.
The P/E ratio of Rubra Medicaments Ltd is 503.52 times as on 18-Jun-2025, a 0% premium to its peers’ median range of 503.52 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rubra Medicaments Ltd and enter the required number of quantities and click on buy to purchase the shares of Rubra Medicaments Ltd.
Rubra Medicaments Limited engages in the trade of pharmaceuticals, and other medical and surgical products in India. The company was incorporated in 1991 and is based in Mumbai, India.
There is no promoters in Rubra Medicaments Ltd.
There is no promoter pledging in Rubra Medicaments Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
5,195
|
|
|
134
|
|
|
53
|
|
|
26
|
|
|
11
|
|
|
9
|
|
|
9,692
|
|
|
9,644
|
|
|
9,040
|
| Rubra Medicaments Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
4.09
|
|
Operating margin(%)
|
9.2
|
|
Net Margin(%)
|
4.79
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Rubra Medicaments Ltd was ₹0 Cr.
₹0.45
(
